Allergy Therapeutics announces update to Grass MATA MPL phase III clinical programme

Allergy Therapeutics (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has provided an update on its Grass MATA MPL phase III study, due to start in Autumn 2020.

Following further investigation of the phase III Birch MATA MPL study (B301), the upcoming Grass study will now take a stepwise approach, with two stages covering both the 2020/2021 and 2021/2022 pollen seasons, rather than the single large trial originally planned for the 2020/2021 season.

The study’s stepwise approach has been designed with input from allergy experts. It enables a phase III-scale study to begin in the 2020/2021 season, followed by an interim review to gain insights into the trial, before continuing to the second part of the study.  

Results from the Group’s successful G205 phase II clinical study, which completed in 2018, evaluating the dose to be taken into phase III, were recently published in the World Allergy Organisation Journal. The paper “Strong dose response after immunotherapy with PQ grass using conjunctival provocation testing” reports that the immunotherapy demonstrated a highly statistically significant (p<0.0001), monotonic dose response for all pre-specified models, which has enabled the Group to acquire agreement from regulatory authorities in Europe and the USA on a target dose for the phase III clinical programme.

Manuel Llobet, CEO of Allergy Therapeutics, said: “The planning for our Grass MATA MPL phase III study is now completed and we look forward to starting this important trial.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
Allergy therapeutics plc

More articles like this

Allergens dominate UK food recalls, finds study

More than half of food recalls in the United Kingdom over a 5-year period were due to allergens, according to a recently released study. Allergen-related recalls increased annually until 2019, peaking at 118 before decreasing to

Allergy Therapeutics welcomes new Non-Executive Directors

Allergy Therapeutics announced the appointments of Anthony Parker and Simon Shen to its Board as Non-Executive Directors effective immediately. “I would like to welcome Anthony and Simon. Southern Fox and ZQ Capital have been long-standing and supportive shareholders of Allergy

Allergy Therapeutics updates on its clinical programmes

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced that the first subject has been dosed in the pivotal Phase III G306 trial, to evaluate the efficacy and safety of

Allergy Therapeutics appoints two Non-Executive Directors

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has today announced the appointments of Anthony Parker and Zheqing (Simon) Shen as Non-Executive Directors of the Company, with immediate effect. Anthony represents

Allergies and Thanksgiving

As Thanksgiving and other holiday celebrations bring people around the table, Intermountain Healthcare dietitians say it’s crucial to take food allergies into consideration when planning the big meal. “A response to an allergic reaction can be

Allergy Therapeutics appoints Martin Hopcroft as interim CFO

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced the appointment of Martin Hopcroft to the role of Interim Chief Financial Officer (CFO). Martin will report into Chief Executive

Food business operator fined for allergy breach

A food business operator based in Newcastle, England has been fined in court after serving a dish containing peanuts to a woman with a peanut allergy, resulting in her being hospitalised. According to the Food Standards

Are restaurants taking allergies seriously?

In an engaging panel held at Twickenham Stadium as part of New Food’s Food Safety Conference 2022, experts came together to debate whether food allergy regulations in restaurants are sufficient. Here’s the highlights. Are restaurant allergy

Allergy Therapeutics Subscription to raise £7 million

Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy immunotherapy, today announces a conditional Subscription by the Subscribers, Southern Fox and ZQ Capital (acting through its affiliate SkyGem), to raise £7 million